权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of novel spray dried dispersion formulations to improve oral and pulmonary delivery

开发新型喷雾干燥分散体制剂以改善口腔和肺部递送

基本信息

批准号：
2266759
负责人：
金额：
--
依托单位：
University of Reading
依托单位国家：
英国
项目类别：
Studentship
财政年份：
2019
资助国家：
英国
起止时间：
2019 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=studentship-2266759
关键词：
Development novel spray dried dispersion

项目摘要

Whilst the oral route has always been the preferred option for drug delivery, the inhaled route is attractive both for systemically and locally acting active pharmaceutical ingredients (APIs). Formulation challenges present for both routes however. For example, doses via the inhaled route are often limited to few milligrams due to difficulties in delivering larger doses, whilst for the oral route, the limiting factor for drug absorption and systemic bioavailability is often the API's water solubility.These limitations can potentially be overcome by designing carriers that can improve water solubility, and which can be loaded with larger amounts of API. Preparation of carriers for API delivery will be based on novel technologies established at the University of Reading and by working in collaboration with Quotient Sciences. Key to the approach is the use of co-crystals (crystalline solids of API and carrier molecules) to modify the API's physicochemical properties. For pulmonary delivery this will have the potential to improve the aerosol properties that subsequently maximise API deposition in the lung. For oral delivery we will look to explore the potential to improve drug solubility. One advantage of this approach is the elimination of any chemical modification of the API meaning this technology can potentially be delivered to market in a relatively short period. It has the potential to have a significant impact on many urgent health issues, such as bacterial resistance, cancers and other lung conditions. Co-crystals will be produced using simple-to-complex processes (e.g. spray drying) and will be followed by extensive physicochemical characterisation. The successful candidate will emerge with a set of skills highly relevant to academia and industry.

虽然口服途径一直是药物递送的优选选择，但吸入途径对于全身和局部作用的活性药物成分（API）都是有吸引力的。然而，两种途径都存在制剂挑战。例如，通过吸入途径的剂量通常限于几毫克，因为难以递送较大剂量，而对于口服途径，药物吸收和全身生物利用度的限制因素通常是API的水溶性。这些限制可以通过设计可以改善水溶性的载体来克服，并且可以负载更大量的API。API输送载体的制备将基于阅读大学建立的新技术，并与Quotient Sciences合作。该方法的关键是使用共晶体（API和载体分子的结晶固体）来改变API的物理化学性质。对于肺部递送，这将具有改善气溶胶性质的潜力，所述气溶胶性质随后使API在肺中的沉积最大化。对于口服给药，我们将寻求探索改善药物溶解度的潜力。这种方法的一个优点是消除了对API的任何化学修饰，这意味着这种技术可以在相对较短的时间内交付市场。它有可能对许多紧迫的健康问题产生重大影响，如细菌耐药性、癌症和其他肺部疾病。共晶将使用简单到复杂的工艺（例如喷雾干燥）生产，然后进行广泛的理化表征。成功的候选人将出现一套与学术界和工业界高度相关的技能。